Trial Profile
Effects of iNO on Invasively Derived Pulmonary Vascular Parameters in Patients With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 23 May 2017 New trial record
- 07 Apr 2017 According to a Bellerophon Therapeutics Media Release, results presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT, 2017).
- 07 Apr 2017 Results published in a Bellerophon Therapeutics Media Release.